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Regulation of glucose metabolism of natural phytochemicals for the management of 
type 2 diabetes mellitus 
 
Abstract: Type 2 diabetes mellitus (T2DM) is the most prevalent disease and becoming a 
serious public health threat worldwide. It is a severe endocrine metabolic disorder which 
has the ability to induce serious complications in all kinds of organs. Although the 
mechanisms of anti-diabetics have been described before, we focus here on the cellular and 
physiological mechanisms on the modulation of insulin and blood glucose. As obesity and 
inflammation are intimately associated with the development of T2DM, the possible 
relationships of them were described. We investigated and discussed the effects of gut 
microbiota on insulin resistance in human clinical trials and the potential mechanisms and 
roles whereby gut microbiota improve glucose metabolism. Phytochemicals have 
historically underlied their effects with therapeutic potential on T2DM, and nowadays still 
represent an important pool for the identification of novel drug leads. The anti-diabetic 
effects of natural species that are used in medicines or as nutraceuticals were described. 
The objective of the present study was to make a systematic review on glucose metabolism 
in T2DM as well as to explore the relationship between glucose metabolism and natural 
phytochemicals. 
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Diabetes mellitus is a well-known public health issue, affecting 415 million people, 
causing around 5 million deaths and accounting for 14.5% of all-cause mortality worldwide 
in 2015 (International Diabetes Federation, 2015). The World Health Organization reports 
that the worldwide prevalence of diabetes is expected to increase to 642 million by the year 
2040, with many new cases of diabetes occurring in developing countries, especially in 
Asia. This increase in the prevalence of diabetes will inevitably lead to increases in the 
prevalence of diabetes related complications such as retinopathy, neuropathy, and 
cardiovascular diseases. Christian Bommer and colleagues report that the cost of diabetes 
worldwide was USD 1.31 trillion, or 1.8% of the global gross domestic product in 2015 
(Bommer et al., 2017). The global estimation of diabetes expenditures is predicted to 
increase to USD 490 billion in the next 20 years (Zhang et al., 2010a). Type 2 diabetes 
mellitus (T2DM), also known as “non-insulin-dependent diabetes”, accounts for 90% of all 
cases of diabetes and has become an epidemic burden in worldwide. T2DM is the most 
prevalent disease in many modern societies and is becoming a serious public health threat 
worldwide. It is a complex metabolic disorder characterized by insulin resistance (IR) and 
impaired islet β cell function, which together result in an inability to supply sufficient 
insulin to meet the body's demands and eventual β cell loss. Individuals with T2DM 
experience difficulty in controlling their blood sugar level, which leads to high blood sugar 
level, sugar in the urine, and high blood insulin level.  
The prevalence of T2DM in western countries reached an epidemic level and even worse 
in Asian countries in the past decade (Kong et al., 2013). Notably, Asians with T2DM are 
especially vulnerable to renal injury when compared to Caucasians (Kong et al., 2013). In 
Asia, rapid economic development in many countries has driven a great increase in 
diabetes prevalence in the recent decade. The prevalence of T2DM is rising, with many 
Asian countries featured in the top 10 countries with the highest numbers of persons with 
diabetes. Urbanization is linked to reduced physical activity, increased obesity rates, and a 
dietary shift towards more refined carbohydrates and increased fat intake (Ramachandran et 
al., 2008; Ning et al., 2009). Worldwide, China and India are the top two countries with the 
most number of individuals suffer from diabetes, with Indonesia and Japan in seventh and 
ninth place, respectively (International Diabetes Federation, 2015). The prevalence of 
diabetes in South East Asia is also expected to increase by 70% in the next 20 years. Risk 
scores derived in Caucasian populations might not perform well in Asian populations as 
there are different biological factors involved in the development of diabetes. Compared to 
Caucasians, the onset of diabetes in Asians occurs at lower Body mass index (BMI) levels 
and younger ages (Hu, 2011). South Asians also experience early declines in β cell function, 
as well as with more insulin resistant and a younger age of onset of diabetes onset 
compared to other ethnic groups (Gujral et al., 2013; DECODE Study Group, 2003). 
Studies have shown that Asian ethnicities have a 2 to 4-fold risk of developing T2DM 
compared to Caucasian ethnicity (Sacks et al., 2012; Urquia et al., 2011). The mechanisms 
for this increased risk are likely a combination of both genetic and environmental factors 
(Tutino et al., 2014), including the fact that obesity may have a greater effect on insulin 
resistance in these populations compared to Caucasians (Retnakaran et al., 2006). More 
important, genetic factors play a crucial role in the pathogenesis of T2DM in the Asian 
population. A study reported that Asian Indians are excessively IR compared with 
Caucasians (Abate and Chandalia, 2001). More recently, an excess maternal transmission 
of T2DM was identified among Asian Indians (Chaithri et al., 2012). On the other hand, 
many environmental factors, such as diet, lifestyle and BMI, are also reportedly associated 
with the risk of T2DM in Indians (Ramachandran et al., 2001), as well as in other Asian 
populations such as Chinese. The high consumption of white rice especially in East Asian 
is significantly associated with a higher risk of T2DM. The waist-to-stature ratio is more 
strongly associated with T2DM than BMI in most Asian populations. The gut microbiota is 
essential for the development and regulation of the metabolism of the host. The intestinal 
mucosal surface protects the host from pathogenic invasion, is tightly regulated with regard 
to its permeability and can influence the systemic energy balance. Consumption of diets 
high in sugar influences the microbiota composition and leads to an imbalanced microbial 
population in the gut. It has been hypothesized that the gut microbiota could be part of a 
mechanistic link between the consumption of unbalanced diets and T2DM.  
While the causes of T2DM are still not completely understood, it is generally believed 
that T2DM results from both genetic and environmental factors. To date, little attention has 
been focused on glucose metabolism and natural phytochemicals. For this reason, the 
objective of the present study was to make a systematic review on glucose metabolism in 
T2DM as well as to explore the relationship among metabolic pathways, gut microbiota, 
obesity and inflammation. How dietary and microbial metabolites modulate host glucose 
metabolism was also described. 
2. Mechanisms of anti-diabetics 
There are two main pathways for body to adjust the blood glucose, one by insulin 
enhancement, another by glucose metabolism which is without insulin-dependent. Insulin 
secretion by β cells of islets plays one of most important role in our body for adjusting 
blood glucose and essential for insulin-regulated glucose metabolism. Insulin affects the 
blood glucose by one part of glucose influx, glycogen synthesis, glycolysis, and inhibition 
of hepatic glucose production; or the other part of cell proliferation, apoptosis, and 
autophagy (Aikawa et al., 2000; Xing et al., 2015; Kane et al., 2002; Yamaguchi and Otsu, 
2012). Moreover, there are some major metabolic pathways which have been researched 
and reported for explaining the mechanisms of anti-diabetics by insulin (Fig. 1). 
 
Fig. 1. Main metabolic pathways for body to adjust the blood glucose. 
 
2.1. IRS/PI3K/AKT-GLUT4 pathway activators 
Insulin receptor substrate 1 (IRS-1) and IRS-2, the two major substrate proteins 
generated by phosphorylation of insulin receptor, bind to and activate the 
phosphatidylinositol 3-kinase (PI3K). The activation of PI3K is a key step of glucose 
uptake and insulin-induced glucose transport (Tanti et al., 1994). In some extent, the 
protein p85 sub-unit of PI3K can improve the insulin resistance. The generation of 
phosphatidylinos-itol 3,4,5-trisphosphate, which can lead to activate of the three known 
AKT (protein kinase B) isoforms by pyruvate dehydrogenase kinase, isozyme1 (PDK1), 
was accompanied by the activation of PI3K. AKT has been regulated by phosphorylation of 
Thr308 by PDK1 and was a key pleiotropic kinase that affects insulin function on glucose 
metabolism. It can deactivate glycogen synthase kinase (GSK) and inhibit some 
pro-apoptotic factors, such as FoxO3A, FoxO1, and FoxO4 in cell nucleus (Paradis and 
Ruvkun, 1998), and cytoplasm GSK-3β with the development of cell (Mora et al., 2005). 
Meanwhile, it can also activate glucose transporter type 4 (GLUT-4) by 
phosphofructokinase for promoting translocation of glucose (Kadowaki et al., 2012; Kahn 
and Saltiel, 2011; Manning and Cantley, 2007). At the cell surface, GLUT-4 permits the 
facilitated diffusion of circulating glucose down its concentration gradient via muscle and 
fat cells. Within cells, glucose is rapidly phosphorylated by glucokinase in the liver and 
hexokinase in other tissues to form glucose-6-phosphate, which then enters glycolysis or is 
polymerized into glycogen. Glucose-6-phosphate cannot diffuse back out of cells, which 
also serves to maintain the concentration gradient for glucose to passively enter cells 
(Watson et al., 2004). Moreover, GLUT-4 can join the IRS1/2/PI3K/AKT 
signaling pathway as the insulin-regulated glucose transporter. 
2.2. JNK/MAPK/ERK pathway  
  The mitogen-activated protein kinase (MAPK) signaling pathways, including c-Jun 
N-terminal kinase (JNK) and extracellular signal–regulated kinases (Erk) pathway, are one 
of the most importance pathways in models of diabetic and obesity. The JNK signaling has 
been shown to contribute to a variety of pathological processes associated with diabetes, 
obesity, heart disease, and cancer (Kane et al., 2002). The molecules JNKs, key members of 
MAPK family, are named after their capacities to phosphorylate and activate 
the Jun family of AP-1 transcription factors (Chang and Karin, 2001; Hibi et al., 1993). 
Compared with classical MAPK/ERK signaling, JNK pathway is more closely related to 
glycometabolism than lipid metabolism. The JNK/MAPK pathway comprises a sequential 
three-tiered kinase cascade. An upstream MAP3K (MEKKs/ASK1) phosphorylates and 
activates the MAP2K (MKK4, MKK7, MKK3, or MKK6), which then regulate the 
downstream MAPKs (such as JNKs/p38 MAP kinase) (Chang et al., 2001; Meloche and 
Pouysségur, 2007). The ASK1 could lead to negative regulation of IRS1 and be deactivated 
by AKT2. MEKKs are activated by Vav proteins and the member of guanine 
nucleotide-exchange factors which are GDP/GTP exchange factors for Rho/Rac GTPases. 
Vav is activated by tyrosine phosphorylation of Syh and SHP-2, which can directly inhibit 
phosphorylation of IRS. Small G-protein can be distributed into Rho, Rac, and Cdc42 for 
its function. In other words, the activation of MEKKs is accompanied with activation of 
cytokines such as Rac and Cdc42. 
  Advances in genomics and molecular genetics have revealed that the extracellular 
signal-regulated kinase (ERK) signaling pathway is known as MAPK pathway and a key 
signaling cascade for modulating multiple cellular functions by phosphorylating and 
inducing its downstream targets (Chen et al., 2001). ERK/MAPK pathway play an 
important role on diabetes and malignancies by regulation of cell differentiation, 
proliferation, growth, apoptosis, gene expression and others (Degen et al., 2012; Mandal et 
al., 2015; Mebratu and Tesfaigzi, 2009; Zhang and Liu, 2002; Reddy et al., 2003). The 
SHP-2 and Syh of Erk/MAPK pathway as initial signaling is the same with JNK/MAPK 
pathway, which initiates the formation of a ‘signalosome’ composed of the tyrosine kinases, 
GRB2/BLNK-related adaptor proteins, signaling enzymes such as PLCγ2, PI3K, and Vav, 
and small GTPases such as SOS and Ras (Goodnow et al., 2010; Harwood and Batista, 
2010). SOS is involved in Ras signaling activation and also acts as a guanine nucleotide 
exchange factor for Rac to transduce signals from Ras to Rac. In addition, the Ras GTPase 
subfamily plays a key role in this pathway and activates the MEKK1/2 by phosphorylation 
of B-Raf or c-Raf. Furthermore, the MEK1/2 can activate ERK kinases (MEK1/2), which 
inhibits Bcl-6, PPARγ or MEK1/2 and induces Egr-1 DNA-binding activity in the nucleus. 
2.3. IRS1/AKT/mTOR-AMPK signaling pathway  
  IRS1/AKT/mTOR signaling pathway represents a key pathway for genetic variation, 
diabetes and obesity by cell growth control and autophagy inhibition in cytoplasm 
(Magnuson et al., 2012; Ganley et al., 2009). PI3K firstly converts 
phosphatidylinositol-4,5-bi sphosphate (PIP2) into phosphatidylinositol-3,4,5-trisphosphate 
(PIP3) which activates AKT2 by PDK1 kinase. After that, the activated AKT2 inactivates 
the conserved serine/threonine protein kinases mTOR (mammalian target of rapamycin) by 
Rheb-GTPase, which be controlled directly or indirectly by AKT2, or indirectly most likely 
through the control of tuberous sclerosis complexs (TSC1/TSC2). Finally, mTOR inhibits 
ribosomal protein S6 kinase (p70S6k) which intensely inhibits phosphorylation of IRS1 
(Yin et al., 2017). However, AMP-dependent protein kinase (AMPK) signaling is opposite 
of IRS1/AKT/mTOR pathway and gets in touch with each other by Erk1/2 in cytoplasm. 
AMPK has been identified as a critical positive regulator of autophagy, especially as an 
emerging drug target for T2DM and the metabolic syndrome (Hardie, 2011; Zhang et al., 
2009). AMPK not only directly activates IRS1 and participates in blood glucose 
metabolism, but also induces autophagy by inhibition of AKT/mTOR pathway. The 
received signal from cytomembranc stimulated an increase in AMP/ATP ratio and 
activation of AMPK under low-glucose conditions. 
 
3. Tissues in the regulation of glucose homeostasis 
T2DM is a not contagious and severe endocrine metabolic disorder which has the ability 
to induce serious complications in various organs (Su et al., 2017). In insulin-sensitive 
organs such as skeletal muscle and adipose tissue, epigenetic modifications might be 
important in the pathogenesis of T2DM, as the changes alter the profile of genes that 
control glucose metabolism (Fig. 2). T2DM is characterized by the increase in blood 
glucose levels. Insulin secretion can increase in hepatic glucose output and de-nove 
lipogenesis. T2DM has all inability of tissue cells to utilize secreted insulin against glucose 
intolerance. (Catalogna et al., 2016; Sharabi et al., 2015; Gugliucci, 2016). It can cause 
severe secondary complications such as liver dysfunction, kidney failure, heart attack and 
nerve damage (Manna et al., 2010; Lastra et al., 2010; Hoshino et al., 2016; Jin et al., 2015). 
The life-threatening T2DM associated complications include long-term damage, 
dysfunction and failure of the vital organs such as eyes (retinopathy), kidneys 
(nephropathy), peripheral nerve (neuropathy) and heart vessels (cardiovascular diseases). 
Pancreas plays a critical role in glucose homeostasis through secreting glucose-lowering 
hormone insulin and its opponent glucagon (Lovorka et al., 2016). It can decrease blood 
glucose levels by reduced triglycerides levels, promoted oxidative stress and improved the 
function of antioxidant enzymes (Okoli et al., 2010; Ren et al., 2013; Roy et al., 2016). 
However, impaired insulin secretion by pancreatic -cells or loss of cell mass and function 
to insulin biosynthesis can increase -cells apoptosis and let -cells proliferation down, 
which is reflect on higher blood glucose levels (Rutter et al., 2015; Keane and Newsholme, 
2014; Mohan et al., 2015). Sustained hyperglycemia can lead to dysregulated glucagon 
secretion by pancreatic -cells and elevated glucagon concentration (Song et al., 2014). 
Liver also plays an important role in T2DM ameliorating via participating in PKC 
phosphorylation, P13K/AKT and AMPK signaling regulation (Steinbrenner, 2013), 
GLUT1/4 and glutathione (GSH) synthesis, while decreased glutamic-pyruvic transminase 
activity (GPTA), mTOR/S6K and oxidative stress (Cordero-Herrera et al., 2015). Other 
tissue cells are unable to utilize the secreted insulin, thus conduce to high hepatic glucose 
output, increase in hepatic glucose, glucose production, and de-nove lipogenesis (Catalogna 
et al., 2016; Sharabi et al., 2015; Gugliucci, 2016). 
Hyperglycaemia promotes lipid accumulation and glucose reabsorption caused by 
upregulation of sodium-dependent glucose transporters 2 (SGLT2) receptors in the diabetic 
kidney (Vallon and Thomson, 2017). Furthermore, it has been proven that proinflammatory 
cytokines such as MCP-1, TGF-β1 and ICAM1 play a key role in the development of 
diabetic nephropathy (Du et al., 2015). And the kidney either improved albuminuria or 
(National Kidney Foundation, 2012). Persistent hyperglycaemia not only promotes the rate 
of glucose absorption and slows gastric emptying in stomach, but also inhibits 
cardioprotection and cardiac function (Maji and Samanta, 2017; Chen et al., 2017). 
Impaired insulin resistance induced neurotransmitter dysfunction (Hiriart et al., 2014), 
declined neuroprotection, increased appetite and reduced satiety (João et al., 2016). In 
addition, insulin inhibits gluconeogenesis and initiates glucose uptake in the muscle and 
adipose tissues for the maintenance of normal blood glucose levels. Adipose tissue acts as a 
critical metabolic organ and produces a number of hormones and cytokines such as 
adiponectin, leptin, AMPK, GLUT4, AKT, TNFα, IL6 and MCP1 (Thea et al., 2015; Zhang 
et al., 2016). Adiponectin separated from adipose tissue has an insulin-sensitizing and 
antiatherorgenic activity. However, hyperglycaemia enhanced lipolysis and endothelial 
dysfunction. Besides, high blood glucose levels inhibit incretin response and lead to 
glucose absorption and abnormal gut microbiota (Zappas et al., 2017). 
 
Fig. 2. Tissues in the regulation of glucose homeostasis 
 
4. Type 2 diabetes, obesity, and inflammation  
Obesity is strongly associated with an increased risk of T2DM and cardiovascular 
disease. These conditions are also now recognized as having an inflammatory component 
(Fig. 3). A number of cytokines and inflammatory signaling pathways have been shown to 
be involved in the development of T2DM, as indicated by increased serum levels of several 
inflammatory biomarkers, including tumor necrosis factor-α (TNF-α), C reactive protein 
(CRP), high molecular weight adiponectin, and interleukin (IL)-6. The potential role of 
inflammation in the complications of obesity is offering further insight into the relationship 
between T2DM and cardiovascular disease has led to a greater interest on specific 
therapeutic targeting. Glucagon-like peptide-1 (GLP-1) is a gut hormone, secreted from the 
intestine in response to meal ingestion, which stimulates insulin secretion and inhibits 
glucagon release in a dose-dependent fashion (Mazidi et al., 2017). Diabetes is known to 
have an important inflammatory component. Poor glycaemic control has been found to be 
positively correlated with levels of inflammatory cytokines such as IL-6 and IL-1β in the 
circulating blood stream (Calle and Fernandez, 2012). Studies have also shown that the 
benefit of anti-inflammatory medication as a means of treatment for T2DM (Weisberg et al., 
2008). Despite a difference between systemic and neuroinflammation due to the action of 
the blood brain barrier, there may indeed be some cross-over. Cytokines are now thought to 
have the ability to cross the blood brain barrier. There is evidence that a hyperglycaemic 
state increases blood brain barrier permeability (Hawkins et al., 2007). Thus diabetes is 
relate to a heightened systemic inflammatory response and increased susceptibility of the 
inflammatory cytokines to enter the central nervous system (Perry et al., 2017). 
 
Fig. 3. The relationships among type 2 diabetes, obesity, and inflammation. 
 
5. Effects of gut microbiota and metabolic endotoxemia/bacteremia on diabetes 
5.1 Altered gut microbiota composition in diabetes 
  The endogenous gut microbiota is considered to be a “forgotten organ” participates in 
whole-body metabolism (O'Hara and Shanahan, 2006). There are approximately 1014 
bacteria belonging to more than 1,000 phylotypes in human gut (Whitman et al., 1998). 
Although the composition of human gut microbiota shows vary greatly between individuals, 
most of bacteria belong to six well known bacterial divisions/phyla: Firmicutes, 
Bacteroidetes, Proteobacteria, Actinobacteria, Fusobacteria, and Verrucomicrobia 
(Lozupone et al., 2012; Eckburg et al., 2005), The abundance of Bacteroidetes and 
Firmicutes comprise the population of 60%-90% of the consortium yet (Neish et al., 2009). 
Healthy human gut mainly harbors anaerobic bacteria, which of the number is far more 
than aerobic and facultative anaerobic bacteria (Sommer and Bäckhed, 2013). They are 
comprised of predominant obligate anaerobes which are belonging to the genera 
Bacteroides, Eubacterium, Clostridium, Ruminococcus, Peptococcus, Peptostreptococcus, 
Bifidobacterium, and Fusobacterium. The following subdominant facultative anaerobes are 
Escherichia, Enterobacter, Enterococcus, Klebsiella, Lactobacillus, and Proteus (Guarner 
and Malagelada, 2003). However, our gut just harbors limited numbers of archaea (mainly 
Methanobrevibacter smithii), eukary (mainly yeasts) and viruses (mainly phage) (Reyes et 
al., 2010). Several experimental reports have suggested that diet plays a dominant role in 
forming and changing the bacterial community composition of human gut (Hildebrandt et 
al., 2009). Moreover, the compositional changes in gut microbiota represent an etiological 
factor in the development of both insulin resistance and T2DM. Recent studies have shown 
the gut microbial inhabitants have an influence on the onset of metabolic diseases such as 
obesity and diabetes. Turnbaugh et al. (2006) confirmed obesity is associated with the shift 
in relative abundance of the two dominant bacterial phyla, the Firmicutes and the 
Bacteroidetes. Specifically, a larger proportion of Firmicutes and relatively lower 
abundance of the phylum Bacteroidetes were observed in obese individuals, suggesting that 
both of them were correlated with energy intake and adiposity (Murphy et al., 2010; 
Ravussin et al., 2012). At the level of class and below of the microbes, alterations in 
microbiota composition and diversity have been also involved in obesity-induced IR and 
T2DM. In contrast to obesity, T2DM-associated microbial dysbiosis is comparatively 
modest. The gut microbiome in T2DM was lower levels of short-chain fatty acids 
(SCFA)-producing bacteria (Eubacterium rectal, Faecalbacterium prausnitzii, Roseburia 
intestinalis and etc.) and higher levels of known or potential opportunistic pathogens 
(Clostridium hathewayi, C. ramosum, and Eggerthella lenta) (Qin et al., 2012). And 
previous studies have shown that functional changes in gut microbiota contribute to the 
increases in plasma glucose concentrations (Clemente et al., 2015). A moderate degree of 
gut microbial dysbiosis have appeared on diabetes. Influence of gut microbiota on the 
development of diabetes is summarized in the present review (Fig. 4). 
5.2 Gut microbiota and host energy balance and storage 
  The gut microbiota was reported to participate in the energy energy and general 
metabolic functions through fermenting undigested carbohydrates, which activate host 
satiety and decrease food intake (Chambers et al., 2015). Undigested dietary carbohydrates 
are important sources of energy for human colonic microbiota species, which have the 
capacity to utilize nearly all of the major plant and host complex glycans, such as two 
members of the Bacteroides fragilis group, Bacteroides thetaiotaomicron and B. ovatus 
(Martens et al., 2011). Interestingly, Bifidobacteria are dominant and prevalent members of 
the (early) microbiota are that they may access glycans in the gut through mutualistic 
cross-feeding or resource-sharing activities, which is indicative of 'social behavior' among 
bifidobacterial strains. The short chain fatty acids (SCFAs) are a group of molecules that 
can both modulate the intestinal barrier and escape the gut to influence systemic health. As 
the bacterial fermentation products, SCFAs (principally acetate, propionate and butyrate) 
are readily absorbed by the colonic epithelium (butyrate) and peripheral tissues (acetate and 
propionate) (Lin et al., 2012). SCFAs have been also shown to activate the gut hormones 
glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) through G-protein coupled 
receptor 43/41 (GPR 43/41) which are also known as free fatty acid receptor 2/3 (FFAR 2/3) 
(Kaji et al., 2014). Several seminal researches showed that GLP-1 and PYY suppress 
appetite and energy intake (Lin et al., 2012; Nøhr et al., 2013; Tolhurst et al., 2012). Kjems 
et al. (2003) reported that GLP-1 led to increased insulin secretion in T2DM patients. The 
activated GPR 43 inhibits fat accumulation in adipose tissue and promotes the glucose 
metabolism in other tissues by suppressing insulin signalling in adipocytes (Kimura et al., 
2013). The SCFA receptor GPR43 also participates in regulation of inflammatory responses 
in immune cells (Maslowski et al., 2009). Butyrate and acetate were reported to elevate 
AMP-activated protein kinase (AMPK) activity (Gao et al., 2009; Sakakibara et al., 2006). 
AMPK activation enhances cellular energy levels by stimulating glucose transport and fat 
oxidation as well as inhibiting the synthesis of fatty acid and glycogen (Inoki et al., 2012). 
Moreover, as a histone deacetylase 6/9 (HDAC 6/9) inhibitor, butyrate was proved to 
promote FoxP3 expression and both the number and function of FoxP3 (+) Treg cells 
(Beier et al., 2012; Tao et al., 2007). On the other hand, the gut microbiota promotes fat 
storage through suppressing the fasting-induced adipose factor (Fiaf) which is a circulating 
lipoprotein lipase (LPL) inhibitor in the gut epithelium (Bäckhed et al., 2007). The 
increased LPL activity was associated to the microbiota-induced deposition of triglycerides 
in adipocytes and adipose tissue (Backhed et al., 2004). The gut microbiota also markedly 
enhances the hepatic triglycerides synthesis by activating the gene expression of the two 
key transcriptional factors, carbohydrate response element binding protein (ChREBP) and 
sterol response element binding protein 1c (SREBP-1c) (Shen et al., 2013). ChREBP and 
SREBP-1c are both critical for hepatocyte lipogenesis due to their independent effects on 
mediating glucose signaling and insulin action in liver respectively, thus improving glucose 
absorption and insulin levels (Dentin et al., 2004). Hence, the influences of gut microbiota 
on host energy balance and storage represent a possible pathway linking gut microbiota and 
obesity and diabetes.  
5.3 Metabolic endotoxemia/bacteremia, gut barrier function and diabetes 
  Gut microbiota-derived metabolic endotoxemia are reported to participate in the onset 
and progression of inflammation and metabolic complications. Several studies have 
demonstrated dietary fat facilitates the development of metabolic endotoxemia, such as 
bacterial lipopolysaccharide (LPS) that is a component of the cell wall of Gram-negative 
bacteria (Amar et al., 2008). LPS is one of the pathogen-associated molecular patterns 
(PAMPs), PAMPs also include peptidoglycan (PGN), flagellin and lipoproteins etc. The 
PAMPs are recognized by the pattern-recognition receptors (PRRs), including the Toll-like 
receptors (TLRs) and the Nod-like receptors (NLRs). The interaction between the PRRs 
and the PAMPs induces cytokine and interferon production, which may activate the 
proinflammatory signaling cascades in peripheral tissues of the body (Icaza-Chávez, 2013). 
LPS and PGN molecules bind to TLR4 and NOD1 receptors respectively, activation of 
which by the gut microbiota get involved in diet-induced inflammation and insulin 
resistance (Cani et al., 2007; Schertzer et al., 2011). TLR5 is expressed on the apical and 
basolateral surface of intestinal epithelia, which detects bacterial flagellin from both 
Gram-positive (e.g., Listeria monocytogenes) and Gram-negative bacteria (e.g., Salmonella 
typhimurium) (Hayashi et al., 2001). The activation of TLR5 strongly promoted nuclear 
factor NF- Letran et al., 2011). It is well 
known that gut mucosal surface is the key site of pathogenic bacteria and metabolic 
endotoxemia entry into the body. Endocannabinoid lipids anandamide (AEA) and its 
receptors cannabinoid receptors 1 (CBR1) in endocannabinoid (eCB) system are involved 
in the regulation of gut barrier function during obesity (Alhouayek and Muccioli, 2012). 
Muccioli et al. (2010) found the gut microbiota regulates the CB1R expression and AEA 
content in the intestine. Furthermore, the eCB system regulates epithelial permeability 
through the distribution and localization of tight-junction proteins, e.g. Zonula Occludens-1 
(ZO-1) and occluding (Muccioli et al., 2010). Additionally, mucus layer has long been 
recognized as an important ingredient providing protective gut barrier for the host. Muc2 is 
the major glycosylated mucin produced in the small and large intestine (Johansson et al., 
2008). Normal gut microbiota can stimulate the secretion of Muc2 mucin in the goblet cells 
to ensure the integrity of the mucous layer structure, and thus maintain gut barrier function 
(Johansson et al., 2011). Altogether, improvement of gut barrier integrity reduces metabolic 
endotoxemia and bacteremia, as well as lowers inflammation and glucose intolerance. 
Recently, intestinal alkaline phosphatase (IAP) is recognized to play a crucial role in LPS 
detoxification by dephosphorylating and detoxifying the phosphate residues of LPS (Bates 
et al., 2007). Expression of IAP has been shown to be regulated by the gut microbiota and 
its activity could be increased through the diet (Lallès et al., 2010). Therefore enhanced 
IAP activity may contribute to reduction of metabolic endotoxaemia and gut permeability 
in T2DM and obesity. Future physiological studies are needed to elucidate how the 
intestinal branched chain amino acids and other amino acids enter the bloodstream and 
from which intestinal location they are absorbed. Furthermore, investigations of how 
dietary changes alone or in combination with microbial or pharmacological interventions 
may impact the microbiome and, in particular, influence P. copri modulation of serum 
branched chain amino acids levels will open novel avenues to counter the pathogenesis of 
IR and its linked epidemics of common metabolic and cardiovascular disorders. Gut 
microbiota are also responsible for the extensive metabolism of phytochemicals such as 
polyphenols and hence improving the oral bioavailability of phytochemicals and shaping 
their antidiabetic activities (Eid et al., 2017). 
 
Fig. 4. Effects of gut microbiota and metabolic endotoxemia/bacteremia on diabetes 
mellitus 
Probiotics and/or prebiotics could be a promising approach to improve insulin sensitivity 
by favourably modifying the composition of the gut microbial community, reducing 
intestinal endotoxin concentrations and decreasing energy harvest. The anti-diabetic effects 
of probiotics include reducing pro-inflammatory cytokines via a NF-κB pathway, reduced 
intestinal permeability, and lowered oxidative stress. SCFAs play a key role in glucose 
homeostasis through multiple potential mechanisms of action. The potential mechanisms of 
action could involve insulinotropic and satiety effects mediated by gut hormones, GLP-1 
and peptide YY, a β-cell-protective effect by reduced oxidative stress and lowered 
pro-inflammatory cytokines, anti-lipolytic activities and enhanced insulin sensitivity via 
GLUT4 through the upregulation of AMPK signalling in tissues (Favaretto et al., 2014). 
The activation or suppression of the TLRs by microbial signals can dictate the tone of the 
immune response, and they are implicated in regulation of the energy homeostasis. As 
modulators of the immune response, the microbiota-derived signals influence functions of 
distant organs and can change susceptibility to metabolic diseases (Spiljar et al., 2017). 
 
6. Selected Bioactive Natural Products for Diabetes Mellitus 
Several plant and mushroom species, including a number of those have been used in 
traditional Chinese medicine (TCM), have now been shown to have anti-diabetic effects. 
The future potential of the bioactive natural products used in diabetes treatment will be 
based on the modification of structures of biologically active compounds (leads), which is a 
primary requirement for drug development. New approaches for the identification, 
characterization, and resupply of natural products are being developed, that may address 
some of the challenges related to the development of plant-based therapeutics. Resupplying 
from the original plant species is very unfeasible to meet the huge market demands upon 
commercialization of a natural product, and alternative resupply approaches are being 
developed that rely on biotechnological production or chemical synthesis. Over 9000 herbs 
have known medicinal applications among various cultures and countries. Many plants 
have been investigated for their beneficial use in different types of diabetes and reported in 
numerous scientific journals. Some medicinal plants are described below which play a key 
role in managing diabetes. TCM has a long history and has accumulated considerable 
clinical experiences, which form a comprehensive and unique medical and cultural system. 
However, understanding the scientific material basis of TCM herbal formulae at the 
molecular level and from a systematic perspective for evidence-based TCM remain a 
considerable challenge. 
Scientists have discoveried that plants have great efficacy to produce numerous bioactive 
molecules dealing with the problem of diabetes mellitus in recent years. These natural 
products contain large quantities of bioactive compounds including flavonoids, 
oligo-/polysaccharides, terpenoids, curcumin, xanthones, thiosugar derivatives, tannins, 
chalcones, phenolic acids, alkaloids and amino acids (Goto et al., 2010). And it is crucial to 
understand the mechanism behind the biological effects of these compounds for the 
prevention and treatment of T2DM. Flavonoids are a group of bioactive compounds that 
usually found in fruits, vegetables, herbs and other plant foods. The routine hyperglycemic 
period can be responsible for deleterious effects due to glucose toxicity. Flavonoids can 
improve the situations in some case. For example, apigenin regulates hyperglycemia by 
increasing the serum insulin level; anthocyanins prevent the diabetes contribute to the 
antioxidant property; rutin can improve insulin resistance and increase glucose uptake by 
enhancing the activities of many enzymes (Raut et al., 2016); and quercetin regulates the 
diabetes by stimulating insulin secretion, inhibiting aldolase reductase in diabetic patients 
(Bahman et al., 2014). So, polysaccharides are a class of important compounds that 
preventing T2DM. Ganoderma lucidum polysaccharides decreased plasma insulin 
concentration and reversed HFD-induced systemic insulin resistance. GLP ameliorated 
low-grade chronic inflammation, inducing lipolysis in adipose tissues. GLP decreased 
plasma triglyceride and non-esterified fatty acid outflux by suppressing mRNA expressions 
of hormone-sensitive lipase, fatty acid binding protein 4, tumor necrosis factor-α, and 
interleukin-6 in epididymal fat. GLP also regulated composition of gut microbiota 
implicated in T2DM development (Xu et al., 2017). There are six possible mechanism of 
polysaccharides to T2DM as follows: (1) elevating plasma insulin, and declining pancreatic 
glucagon; (2)increasing insulin sensitivity, and improving insulin resistance; (3) scavenging 
free radicals and lipid peroxidation; (4) increasing hepatic glycogen and inhibiting sugar 
dysplasia; (5) restricting α-glycosidase enzymes in bowel, and reducing carbohydrates 
decomposition and absorption (Wang et al., 2017). Studies also found that the mechanism 
of terpenoids to diabetes through reducing blood glucose level, increasing glycogenesis and 
decreasing glycogenolysis, inhibiting aldose reductase can also achieve same efficacy. 
Curcumin is a natural compound that extracted from root of Curcumalonga, it is known to 
all that curcumin has anti-carcinogenic and anti-oxidant effects (Duvoix et al., 2005; 
Shishodia et al., 2005). Its anti-diabetes attribute to inhibiting insulin-regulated GLUT4 
translocation and glucose transport (Nabavi et al., 2015). Curcumin by reducing 
hyperglycemia reported to subside the oxidative stress caused by reactive oxygen species 
and lipid peroxidation (Raut et al., 2016). Xanthones posses antidiabetic activity due to it 
have mangiferin and glycoside. The mangiferin have two mechanisms such as decreasing 
resistance and /or increasing sensitivity, and its glycoside can against several 
carbohydrate-metabolizing enzymes (Raut et al., 2016). Thiosugar derivatives show strong 
inhibitory activity against a-glucosidases. Tannins can produce denaturation of proteins and 
therefore, promoting the nonspecfic inhibition of α-glucosidase, condensed tannins can 
inhibit α-amylase and higher inhibition can be achieved if the degree of polymerization 
increases. The antidiabetic of chalcone might attribute to the anti-atherosclerotic activity of 
2-hydroxy-4’-methoxychalcone, which has been reported to stimulate PPAR-γ mRNA and 
protein expression in human aortic smooth muscle cells. The group of chalcone would 
enhance the sensitivity to insulin. The possible antidiabetic of phenolic acids has been 
found that they can elevate glucokinase activity and produce the glycogen in the liver. It 
has been observed that the gallic acid posses antidiabetic activity by inducing glucose 
uptake by stimulating the GLUT4 translocation. Recent literature data supports the 
argument that polyphenols can inhibit pancreatic α-amylase or α-glucosidases and this is an 
important mechanism involved in their hypoglycemic effect. Dietary polyphenols rely on 
modification either by host digestive enzymes or those derived from the IM for absorption 
to occur. In the polyphenol-related studies, a large amount of inter-individual variation was 
observed in the microbial metabolism and absorption of certain polyphenols (Shortt et al., 
2017). S-allylcysteine (SAC) is a sulfur-containing amino acid which can promote the 
uptake and metabolism of glucose. Furthermore, it can also produce insulin thereby 
decreasing the blood glucose levels. The antidiabetic mechanism of alkaloids can be 
described two points: (1) by repairing or proliferation of pancreatic β-cells, stimulating the 
secretion of insulin, increasing the sensitivity to insulin, decreasing resistance, increasing 
glycogenesis and inhibiting gluconeogenesis; (2) by decreasing in level of glucogenic 
enzymes. From the foregoing, it is obvious that plants from nature products have powerful 
potential to produce many bioactive molecules which posses pharmacological activities 
especially antidiabetic. 
In addition, phytochemicals such as fiber, polyphenols and polysaccharides play a vital 
role in modulating gut microbiota (phylum Bacteroidetes, Firmicutes and 
Firmicutes/Bacteroidetes ratio, and genus Akkermansia, Bifidobacteria, Lactobacillus, 
Bacteroides and Prevotella) through SCFAs, BAs, LPS (Lyu et al., 2017). The 
administrations of natural phytochemicals lead to increase the abundance of phylum 
Bacteroidetes, and genus Akkermansia, Bifidobacteria, Lactobacillus, Bacteroides and 
Prevotella, while reducing phylum Firmicutes and Firmicutes/Bacteroidetes ratio in gut. 
Natural phytochemicals interact with gut microbiome and alter the microbial metabolites 
including SCFAs, bile acids (BAs) and lipopolysaccharides (LPS), which are correlated 
with T2DM.  
 
7. Challenges and Perspectives 
Why does T2DM get progressively worse over time, what is the most effective way to 
slow or prevent progress? The growing prevalence of obesity and T2DM results in an 
overload of patients at very high short-term cardiovascular risk, and therefore there is a 
great amount of interest in research into new treatments for T2DM. There is an increasing 
need for new options to treat diabetes, especially T2DM, at its early stages due to an 
ineffective control of its development in patients. 
7.1 The modification of natural products for medical use 
Although the natural products are normally valuable lead compounds, seldom can they 
be directly used in clinical applications. From the standpoint of drug innovation, it is 
necessary to modify natural product structures, because the aim in generation of secondary 
metabolites by organisms is to protect themselves from natural enemies as well as the 
environment. The final aim of modifying natural products is to developactive compounds 
into medicines. Structural modifications are necessary. The strategy for structural 
modification is to increase potency and selectivity, to improve physico-chemical, 
bio-chemical, and pharmacokinetic properties, to eliminate or reduce adverse effects, to 
simplify the structural complexity, including removal of redundant atoms and chirality 
while retaining activities, and to generate patentable compounds. For example, the natural 
product O-glucoside phlorizin is a well-documented, potent glucosuric agent that was 
subsequently shown to be a nonselective SGLT inhibitor. Because of its inhibition of 
SGLT1 with poor metabolic stability due to its susceptibility to β-glucosidase-mediated 
cleavage, as a lead compound, was modified. Canagliflozin, simplifying structures from 
phlorizin, entered into clinical trials and was approved by the FDA in 2013 for the 
treatment of T2DM (Nomura et al., 2010). 
7.2 MicroRNAs as pharmacological targets in diabetes 
Recently, a novel class of small non-coding RNAs with approximately 22-nucleotides, 
termed microRNAs (miRNAs), is found to play a key role as important transcriptional and 
posttranscriptional inhibitors of gene expression in fine-tuning the target messenger RNAs. 
It is predicted that over 30% of human genes are regulated by miRNAs which are 
implicated in the pathogenesis of T2DM and have become an intriguing target for 
therapeutic intervention. Recent data suggest that miRNAs play a direct role in insulin 
secretion pancreatic islet development, β cell differentiation, and indirectly control glucose 
and lipid metabolism and are involved in secondary complications associated with diabetes. 
MiRNAs are regarded to regulate insulin biosynthesis and secretion in pancreatic β-cells, 
insulin sensitivity in skeletal muscle and adipose tissue, as well as glucose and lipid 
metabolism in liver. The first evidence of miRNAs controlling the β cell activities was 
demonstrated by Poy and his colleagues (Poy et al., 2004). Specific miRNAs play a critical 
role in controlling β cell activities and the development of diabetic vascular complications. 
The ubiquity of miRNAs in body fluids and their association with the disease pathogenesis 
have made them important players for prognosis, diagnosis and management of T2DM.  
MiR-375 was reported to regulate secretory activities of β cells. Silencing of miR-375 
increases glucose-stimulated insulin secretion in murine pancreatic β cell lines (MIN6) and 
isolated primary β cells. MiR-375 knockout mice exhibited increased pancreatic α-cells, 
elevated plasma glucagon levels, gluconeogenesis and hepatic glucose output. MiR-7a was 
recognized to be a negative regulator of adult β cell proliferation by targeting various 
components in mTOR signaling pathway (Wang et al., 2013). The specific overexpression 
of miR-200 in β cell induced β cell apoptosis and promoted severe T2DM under stressed 
condition by negatively regulating β cell chaperone Dnajc3 or p58IPK and caspase 
inhibitor Xiap in mice model (Belgardt et al., 2015). Previous findings have reported 
various miRNA signatures associated with the T2DM, newly diagnosed cases and vascular 
complications. Although there are multiple numbers of informative studies implicating the 
role of specific miRNAs in β cell biology, they were mainly carried out with cell lines in 
vitro. Thus, it is of great necessity and urgency to validate of those studies in vivo settings 
no pathophysiological conditions. There is a need to obtain more studies on miRNA 
expression in human samples highlight the potential roles of miRNAs in T2DM 
progression. However, pharmacological over-inhibition or overexpression by 
administration of miRNA mimics or miRNA inhibitors may potentially have off-target 
effects. More substantial research and standardization of techniques are required to 
determine the efficacy and feasibility of miRNAs as routinely used diagnostic approaches 
as well as prognostic markers of T2DM and complications. 
7.3 New therapies for type 2 diabetes mellitus 
There have been numerous studies focus on new anti-diabetes drugs aimed at improving 
insulinopenia with fewer side effects than the current insulinotropes (glucokinaseactivators, 
G protein-coupled receptor ligands, ultra-long acting insulins) and reducing 
hyperglycaemia (gluconeogenesis inhibitors), and even focus on new drugs with unusual 
therapeutic pathways, such as the incretinic therapies (GLP-1 analogues), urinary glucose 
reabsorption inhibitors (sodium-glucose cotrans-porter inhibitors) or inhibitors of other 
metabolic pathways with an effect on T2DM and energy metabolism (diacylglycerol 
acyl-transferase inhibitors, 11-β-HSD1 inhibitors). 
 
8. Conclusions 
The growing prevalence of T2DM results in an overload of patients at very high 
short-term cardiovascular risk. The co-administration of natural products along with 
conventional medicines is believed to induce a modified bioavailability and important 
changes of metabolic pathways. Reports show that most of the patients using chronic 
prescription medications are also associating herbal supplements or vegetal rich diets 
without understanding the risks. Natural compounds should be avoided as supplements for 
patients undergoing chemotherapy in order to avoid the risk of decreased availability. 
Systematic studies are necessary in order to unravel the roles of phytochemicals. This 
problem is also complementary with the fact that even physicians are not always aware of 
the risk of interactions. Several products lead to an increase of the drug concentration when 
administered in short term regimen but may induce an increased metabolism and decreased 
effect after prolonged intake. It approaches to prevention and treatment involving a 
combination of factors, such as diet modifications and regular exercise. Dysbiosis of the 
human gut microbiota impacts the serum metabolome and contributes to insulin resistance. 
Microbial targets may have the potential to diminish insulin resistance and reduce the 
incidence of common metabolic and cardiovascular disorders. The objective of the present 
study was to make a systematic review on glucose metabolism in T2DM as well as to 
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